Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Dermavant Sciences has shared positive long-term results for its plaque psoriasis-approved Vtama (tapinarof) cream in adults ...

Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

Atopic dermatitis can have a significant impact on quality of life in adolescents, so new efficient treatments are needed to ...

Eczema affects millions of Americans, and any number of environmental and health factors can trigger flare-ups. What should ...

Jersey City-based Organon has completed its acquisition of Dermavant Sciences Ltd. from Roivant. Dermavant is a company ...

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.